Selank / SemaxBlend
Selank + Semax nootropic blend for calm focus and recall.
- Status
- Research / not approved
- Developer
- Compounded research-peptide blend; Russian-origin component peptides
- Receptors / target
- Not a single target — combines Selank (tuftsin-analog anxiolytic) and Semax (ACTH(4-10)-analog nootropic); modulates GABA/serotonergic and BDNF/monoaminergic systems
- FDA-approved?
- NO
- Prescription available?
- NO
- Studied for
- anxiety / moodcognition & focusneuroprotectionBDNF / neuroplasticity
Overview
Selank / Semax is a compounded nootropic/anxiolytic peptide blend pairing two Russian-developed neuropeptides: Selank (a tuftsin-analog anxiolytic) and Semax (an ACTH(4-10)-analog nootropic). Both are registered and used as prescription drugs in Russia (intranasally), but neither is approved by the FDA or EMA, and the combination has no clinical trials. It is sold research-use-only and is most often dosed intranasally.
Mechanism
Selank is attributed anxiolytic activity through GABAergic modulation, inhibition of enkephalin-degrading enzymes, and effects on serotonergic and immune signaling. Semax up-regulates BDNF and NGF and modulates monoaminergic systems, the basis of its nootropic/neuroprotective framing. The blend pairs a calming peptide with a stimulating/cognitive one; their combined pharmacology has not been characterized, and most mechanistic work for each is preclinical (rodent).
Clinical evidence
There are no trials of the Selank/Semax blend; evidence is per component and largely Russian- language and low-grade by Western standards. Selank has small Russian clinical studies in generalized anxiety; Semax has Russian clinical use in ischemic stroke and cognition. Neither has been replicated in large, independent, placebo-controlled Western trials, and the strongest mechanistic data are in animal models. Combined benefit claims are unproven.
Safety profile
Short-term Russian clinical and over-the-counter use of each peptide suggests acceptable tolerability (mild nasal irritation with intranasal dosing), and unlike benzodiazepines Selank is not reported to cause dependence. However, rigorous independent safety data are limited, the combination is unstudied, and research-grade material is of unregulated purity. Neither component is FDA-approved, and the blend is not WADA-listed. Research-use only; nothing here is therapeutic or dosing guidance.
- Same day (acute)
Both are used acutely (intranasal), with effects reported within hours of dosing.
- Weeks
Russian single-peptide studies ran over weeks, but there are no trials of the combination and no independent Western data.
Reported in published literature and user reports. Not a complete list, and not medical advice.
- Nasal irritation (intranasal)
- Mild drowsiness or transient overstimulation
- Generally well tolerated short-term
- Limited rigorous safety data outside Russia
If severe or unexpected symptoms occur, contact a qualified medical professional. PEPTIDES·INDEX does not provide medical advice.
- No human safety data exist for the combination; it is unstudied and research-use only, and rigorous independent (non-Russian) safety data for each component are limited.
- Research-grade material is of unregulated, unverified purity.
- Intranasal dosing can cause nasal irritation; effects on those with neurological or psychiatric conditions are uncharacterized.
- No documented human drug interactionsNo interaction studies of the combination; uncharacterized in humans (research use only)
Compare
FAQ
Is the Selank/Semax blend studied in clinical trials?
No. There are no trials of the combination. Evidence is per component and largely Russian-language and low-grade by Western standards — small Russian studies for each, with the strongest mechanistic data in rodents. Combined benefit claims are unproven.
What is in this blend?
Two Russian-developed neuropeptides — Selank (a tuftsin-analog anxiolytic) and Semax (an ACTH(4-10)-analog nootropic) — most often dosed intranasally.
Is it approved or banned in sport?
Both are registered prescription drugs in Russia but neither is FDA- or EMA-approved. The blend is not on the WADA Prohibited List.
Why combine Selank with Semax?
The stack pairs a calming peptide (Selank, attributed anxiolytic activity via GABAergic and enkephalin-related modulation) with a stimulating/cognitive one (Semax, which up-regulates BDNF/NGF and modulates monoamines). The idea is complementary calm-plus-focus effects, but their combined pharmacology has not been characterized and the pairing is supported only by anecdote.
How is the blend administered?
Both component peptides are most often given intranasally (as they are used in Russia), and subcutaneous use is also reported. Both are short-lived in plasma, so they are typically dosed acutely. There is no validated dosing for the combination, and research-grade material is of unregulated, unverified purity. Research use only.
How does the blend compare to its single components?
Each component has small Russian clinical data on its own — Selank in generalized anxiety, Semax in ischemic stroke and cognition — but neither has been replicated in large independent Western trials, and there are no studies of the two together. Combining them does not add evidence; any blend-level benefit remains unproven.
Similar compounds
Starting references for the library summary. These are not dosing instructions or medical advice.
For research-use educational context only. Not medical advice and not a recommendation to use any compound. Consult a qualified healthcare professional before any health decision.